Page 13 - John Tsai News Today : Breaking News, Live Updates & Top Stories | Vimarsana

19. More people die of lung cancer every year than any other cancer type 11. Novartis is committed to developing best-in-class treatments for lung cancer patients around the world. With a focus on both targeted, personalized medicine and the role of newer, immuno-oncology therapies, the lung cancer drug development program at Novartis is among the most robust in the industry. With research activities informed by long-term relationships with leading lung cancer thought leaders and patient advocates, Novartis is focused on reimagining the treatment of lung cancer.   Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “potentially,” “can,” “will,” “expected,” “committed,” “evaluating,” “continue,” “ongoing,” “approximately,” or similar terms, or by expre

United statesIsabella zinckThomas hungerbuehlerSamir shahMary curtin creaserBiochim biophys actaJulie masowSloan simpsonJohn tsaiGlobal oncology communicationsAmerican joint committee on cancerHead of global drug developmentWorld health organizationExchange commissionStrategy financial communicationsNational comprehensive cancer network guidelines